Skip to main content
. 2023 Apr 26;10:1142429. doi: 10.3389/fcvm.2023.1142429

Figure 2.

Figure 2

Incremental cost-effectiveness plane for comparing ablation with drug therapy for the entire CABANA cohort (catheter ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation; N = 2204; A) and the heart failure subgroup with New York Heart Association class ≥II symptoms (n = 778; B). Estimates of incremental costs and quality-adjusted life-years (QALYs) are shown (1 blue circle for each of 5,000 bootstrap samples). Quadrant I represents scenarios where ablation is more costly and less effective, Quadrant II represents scenarios where ablation is more costly and effective, Quadrant III represents scenarios where ablation is less costly and less effective, and Quadrant IV represents scenarios where ablation is less costly and more effective. The willingness-to-pay thresholds of $50,000 and $100,000 per QALY gained are represented as the slope of the green and red lines, respectively. Scenarios that fall below these willingness-to-pay-thresholds are considered economically attractive. (Reproduced from Circulation. 2022;146:535–547 with permission).